Z SQUARED INC (ZSQR)
Health Care · Biopharmaceutical cell therapy and immunotherapy development · NASDAQ
An early-stage biopharmaceutical company developing natural killer cell therapies and CAR platforms for cancer and infectious diseases, complemented by enterprise software capabilities.
What Z SQUARED INC does
Z Squared Inc (formerly Coeptis Therapeutics Holdings) is a biopharmaceutical and technology company developing cell therapy platforms and immunotherapies for cancer, autoimmune, and infectious diseases. The company operates through subsidiaries including SNAP Biosciences and GEAR Therapeutics, focusing on NK cell therapies and CAR-T platforms, while also offering AI-powered marketing software and robotic process automation tools.
Themes: Cell therapy / NK cell immunotherapy, CAR-T and CAR-NK platforms, Cancer therapeutics, Infectious disease treatment, Autoimmune disease, Enterprise AI / process automation
Fundamentals
- Price$3.65 as of 2026-08-21 close
- Market cap$193M as of 2026-08-21
- 1-year return-72.8% 2025-08-21 close $13.43 → 2026-08-21 close $3.65
- P/En/a negative earnings
- Net margin-832.3% as of 2026-08-24
- Gross margin+87.2% as of 2026-08-24
- ROE-99.7% as of 2026-08-24
- Debt / equity0.01 as of 2026-08-24
- Last reported earningsn/a no earnings announcement (Form 8-K, Item 2.02) has been filed in our data yet
How ZSQR compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How Z SQUARED INC looks technically
Z SQUARED INC (ZSQR) is trading 69.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 111 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 41, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 34, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day low, breaking below its recent trading range. It is 1.1% above its 52-week low (its lowest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 69.1% below its 200-day average, the long-term trend line — a long-term downtrend | -69.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $7.62 | $7.62 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $11.81 | $11.81 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 22 calendar days ago — the swings before that are what the structure reading is measured on | 22 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes above 5.6. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 111 trading days ago — a "death cross", a bearish long-term signal | 111 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 41, with sellers in control | 41.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 34, neither overbought (above 70) nor oversold (below 30) | 33.6 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($3.61 to $5.43) — its "stochastic" reading is 2 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 2.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 17 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $21.41 | $21.41 |
|---|---|---|
| From the 52-week high | it is 83.0% below its 52-week high (its highest price of the past year) | -83.0% |
| Above the 52-week low | it is 1.1% above its 52-week low (its lowest price of the past year) | +1.1% |
| Below the 52-week high | it is 83.0% below its highest point of the past year | 83.0% |
| Since a 20-day breakout | it just made a new 20-day low, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $428.40 (set on 2022-10-28) | $428.40 |
| Given back of the 52-week move | over the past year its closes ranged ($3.65 to $18.80), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $13.01 to $13.50. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 99.1% below its all-time high | -99.2% |
| Nearest price level | it is trading 3.0% below a resistance level at $3.76 — a price it turned at twice since 2024-09-30, most recently on 2024-11-21. Since 2024-08-21 it has 0 such levels below the current price and 13 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.0% |
| All-time low | its lowest closing price on record is $2.31 (set on 2024-12-31) | $2.31 |
| Above the all-time low | it is 58.0% above its all-time low | +58.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 49th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.653 between its high and its low — about 17.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.653 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.27 and $5.30 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.27 – $4.28 – $5.30 |
| Typical daily range (% of price) | its price moves about 17.9% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 17.9% |
| Stretch from the 200-day average | it is trading 12.5 daily ranges below its 200-day average price (69.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 12.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.73× |
|---|
Candlestick patterns
2
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bullish engulfing | 6 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.0% |
|---|---|---|
| Open gap | it gapped 2.2% below the previous close 34 sessions ago and has not traded back through the level it left behind at 12.02 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.2% |
| Gap filled | a 3.4% gap down opened on 2026-08-14 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 4 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -11.19% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 33.9 percentage points (the stock lost 31.5% while the market gained 2.3%) | -33.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 58.4 percentage points (the stock lost 55.3% while the market gained 3.1%) | -58.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 79.3 percentage points (the stock lost 68.2% while the market gained 11.1%) | -79.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 93.3 percentage points (the stock lost 72.8% while the market gained 20.5%) | -93.3% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: MACD momentum is positive, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 61% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 33.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -61.1% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 62% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $9.70 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | -62.4% |
|---|
Price levels it has turned at before
ZSQR last closed at $3.65 on 2026-08-21. Since 2024-08-21 it has turned at 0 prices below its last close and 13 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.76 | Resistance | 3.0% above the last close | turned there twice · 2024-09-30 to 2024-11-21 |
| $4.85 | Resistance | 32.9% above the last close | turned there twice · 2024-10-22 to 2024-12-03 |
| $6.81 | Resistance | 86.6% above the last close | turned there twice · 2024-12-26 to 2025-06-20 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes above $5.60.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Near the 52-week low · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Key risks (from latest filing)
["Highly unprofitable with accumulated deficit of $113.9M and negative net margin of -832%, with no clear path to profitability; company is burning cash rapidly with limited runway.","All product candidates remain in pre-clinical or early Phase I/II stages with significant development risk; no approved therapies or near-term revenue generation expected.","Convertible notes in default ($100K) and dependent on equity financing and strategic partnerships (SSA with Deverra ended December 2024); significant dilution risk to shareholders from continued fundraising."]
What changed in the latest 10-Q
AI-assisted comparison of ZSQR's 10-Q filed 2026-05-15 against the prior one filed 2025-11-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Recent Business Combination section describing April 24, 2026 merger with Z Squared, Inc. and issuance of 43,877,497 shares
- Corporate name change from Coeptis Therapeutics Holdings, Inc. to Z Squared Inc. effective April 27, 2026
- Nasdaq ticker symbol change from COEP to ZSQR
- Description of Spin-Out of biopharmaceutical operations to spin-out subsidiaries (Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., Coeptis Pharmaceuticals, LLC, SNAP Biosciences, Inc.)
- Description of principal business as digital asset mining operations including cryptocurrency mining of Dogecoin (DOGE), Litecoin (LTC), and other digital assets at facilities in North Carolina, South Carolina, and Iowa
- Description of complementary business lines including power generation, data center development, and high-performance compute hosting
- Retention of interest in GEAR Therapeutics, Inc. following Spin-Out
- Reference to Registration Statement on Form S-4 (File No. 333-288329) declared effective December 23, 2025
- Reference to Current Report on Form 8-K filed April 24, 2026
- Basis of MD&A Discussion section explaining historical financial statements represent pre-Merger business of legal acquirer
- Caveat that historical financial information is not indicative of or comparable to subsequent periodic reports
- Expanded forward-looking statements language including additional qualifiers: anticipate, plan, may, will, should, would, could, potential, future
- Removed:
- Reference to Merger accounted for as reverse merger with Coeptis Therapeutics, Inc. as accounting acquirer
- Company History section describing incorporation in British Virgin Islands on November 27, 2018 and domestication to Delaware
- Company History describing October 28, 2022 merger with Coeptis Therapeutics, Inc.
- About the Company's Subsidiaries section describing SNAP Biosciences, Inc. and GEAR Therapeutics, Inc. as majority owned, and Coeptis entities as wholly owned
- Company History of Coeptis Therapeutics, Inc. section with detailed formation and merger history
- Overview and Outlook section describing biopharmaceutical and technology company focused on cell therapy technologies for cancer
- Description of two 505b2 anti-hypertension products approved and launched in 2020
- Description of ANDA products divested in 2019
- Reference to strategic partnerships for auto-immune and oncology markets
- Objective section explaining MD&A purpose and context
- Reference to Form 10-K and three and nine months ended September 30 periods
- Specific risk factors reference to failure to develop profitable business, delays in identifying customers, inability to retain customers
- Reworded:
- Forward-looking statements section moved earlier in document structure (after Recent Business Combination rather than before Objective)
- Forward-looking statements now includes Section 21E of Securities Exchange Act of 1934 instead of Section 12E
- Forward-looking statements now specifies reverse acquisition accounting terminology instead of reverse merger
- Financial statements now described as covering three months ended March 31, 2026 and 2025 instead of three and nine months ended September 30
- MD&A scope changed from Coeptis Therapeutics, Inc. and subsidiaries to historical pre-Merger company as legal acquirer
- MD&A explicitly excludes operations of Z Squared as accounting acquirer and Spin-Out Subsidiaries from current period presentation
- Notes:
- Older filing text appears truncated at end (ends mid-sentence with 'innovativ')
- Newer filing text also appears truncated at end of Forward-Looking Statements section (ends mid-sentence)
- Comparison based on available text; full extent of changes may be obscured by truncation
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days.
- Last 30 days1 buy ($3920) · 0 sells — 1 buying insider
- Last 90 days1 buy ($3920) · 0 sells — 1 buying insider
- Last 180 days1 buy ($3920) · 0 sells — 1 buying insider
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-18. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ZSQR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
ZSQR had 4,031,661 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ZSQR had 7.61% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.11 days to cover at the same settlement.
- Reported short interest (shares) 4,031,661
- Short interest (% of shares outstanding) 7.61%
- Prior settlement (shares) 3,746,865
- Reported change 7.6%
- Days to cover (reported) 9.11
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Gilead Sciences (GILD)
- Juno Therapeutics
- Fate Therapeutics (FATE)
- Precision Biosciences (DTIL)
- Tmunity Therapeutics
- Century Therapeutics (IPSC)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ZSQR vs…
Frequently asked questions
What does Z SQUARED INC (ZSQR) do?
Z Squared Inc (formerly Coeptis Therapeutics Holdings) is a biopharmaceutical and technology company developing cell therapy platforms and immunotherapies for cancer, autoimmune, and infectious diseases. The company operates through subsidiaries including SNAP Biosciences and GEAR Therapeutics, focusing on NK cell therapies and CAR-T platforms, while also offering AI-powered marketing software and robotic process automation tools.
What sector is Z SQUARED INC (ZSQR) in?
Z SQUARED INC (ZSQR) is classified in the Health Care sector. Its industry is Biopharmaceutical cell therapy and immunotherapy development. It trades on NASDAQ.
Who are Z SQUARED INC's (ZSQR) competitors?
Notable peers of Z SQUARED INC (ZSQR) include Gilead Sciences, Juno Therapeutics, Fate Therapeutics, Precision Biosciences and Tmunity Therapeutics. This peer set is informational only — not financial advice.
Is Z SQUARED INC (ZSQR) overbought or oversold right now?
Z SQUARED INC (ZSQR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 34, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ZSQR come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.